Learn more about MABA with our co-founder, Yaniv Sneor, on February 27th at 11am (EST) where he will discuss MABA”s investment focus, check sizes MABA can offer, the best time to reach out, and much more.
Register for the Zoom meeting at: https://us06web.zoom.us/meeting/register/tZYuceitqDojGtzt5Pkl2AuR6mTS0O0iiyQe
Posted: January 30, 2023
Happy New Year, and welcome aboard, for those investors who recently joined Sidecar Fund II as investors.
Over the last year, MABA has made several new investments as well as several follow-on investments in existing portfolio companies. A few of these qualified for co-investment by the Fund.
Due to the unique structure of Fund II, which is an open-ended Fund, different investors will end up with different baskets of portfolio companies, depending on the time they joined the Fund.
To make sure that you are able to see updates from the companies in your specific portfolio, we’ve designed and [ Read more… ]
NEW YORK CITY, NEW YORK, UNITED STATES, November 10, 2022 /EINPresswire.com/ — Mid Atlantic Bio Angels Group (MABA) is pleased to announce that it has made an investment in The Shape Sensing Company (TSSC).
TSSC joins a prestigious, carefully selected, group of companies and organizations that reflects MABA’s core mission of supporting early-stage health care entrepreneurs and generating favorable financial returns for its members and investors. The MABA investment included individual investors, MABA’s internal investment Pool III, and the MABA Sidecar Fund II, a co-investment fund for non-MABA members.
“Throughout our due diligence process, TSSC’s strong management and transformative technology received notable [ Read more… ]
Summary
TSSC’s 3D technology can significantly improve device navigation and localization, resulting in safer, faster, and more effective surgical procedures, therefore enabling better patient outcomes, the ultimate goal of medicine.
Documents
The Shape Sensing Company – Update 2023 Q1
MABA Invests in 3D Shape Sensing Technology
Website https://shapesensing.com/
FEMSelect, a company developing EnPlace, a minimally invasive and meshless device for women with pelvic floor issues, raises $9M in Series B funding with participation from Mid Atlantic Bio Angels.
Link to article: https://www.prnewswire.com/news-releases/womens-health-leader-femselect-secures-us9m-series-b-financing-301652846.html
MABA founder Yaniv Sneor participates on an Angel Investors Panel at Digital RESI 2020 where he discusses several topics including what angels (and MABA) look for in a company, how angels prefer to invest (priced rounds, not SAFEs), and the benefits of syndication.
Link to article: https://blog.lifesciencenation.com/2022/07/14/from-mid-size-pharma-to-angels-what-do-investors-say-about-market-downturn/
In this series of interviews with Mindset Startup Academy, MABA founder Yaniv Sneor discusses key to engaging with angel investors.
Link to video: https://www.youtube.com/watch?v=F1flSGw4kkM&list=PLNStBS9BlnPVqTbMQryFOqEh7JlHTAOUO
Summary
Developing digital twin of cells for drug discovery.
Documents
DeepLife Investor Update Oct 2022
MABA Announces First Foray into Digital Health with Investment in Biotech Company DeepLife
Website https://www.deeplife.co/
MABA portfolio company, Healionics, wins the 2020 Luis Villalobos Award from the Angel Capital Association (ACA). The Luis Villalobos Award recognizes ingenious and innovative ideas financed by members of the ACA. Healionics is developing a product to make dialysis safer for those with kidney failure.
Posted: Nov 10, 2019
MABA’s is constantly reviewing new applications for funding, and our yield is fairly consistent. Of every 100 applications, only 24 are invited to present to our group, while 76 are rejected in pre-screening, for a variety of reasons (which we share with the applicants). Of the presenting companies, 16, on average, proceed to due diligence, and, of these, two or three receive funding. These statistics remain fairly consistent, as the number of applications we have reviewed, to-date, exceeds 700.